CriticalProkinetic, peripheral dopamine D2 receptor antagonist×Macrolide antibiotic
Updated · Methodology
Mechanism
Erythromycin is a moderate inhibitor of the enzyme CYP3A4 and of P-glycoprotein (P-gp), and it can raise the levels of drugs metabolised by cytochrome P450 enzymes (erythromycin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and erythromycin label, US Food and Drug Administration, FDA). In the liver, CYP3A4 is the main enzyme that metabolises domperidone, and in vitro data suggest that drugs that markedly inhibit this enzyme may raise domperidone plasma levels (domperidone SmPC, AEMPS). Both drugs prolong the QT interval. During erythromycin treatment, prolonged cardiac repolarisation and QT prolongation have been observed, with a risk of arrhythmia and torsade de pointes (erythromycin SmPC, AEMPS). Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs or CYP3A4 inhibitors (domperidone SmPC, AEMPS). The Spanish domperidone SmPC attributes the contraindication of such combinations to a higher risk of QT prolongation from pharmacodynamic or pharmacokinetic interactions and lists erythromycin among the contraindicated antibiotics. The documents do not say how much erythromycin raises domperidone levels (AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. Rare effects of erythromycin include QT prolongation on the ECG and heart rhythm disorders, including ventricular tachyarrhythmia, palpitations and torsade de pointes. Cardiac arrest and ventricular fibrillation occur at unknown frequency (erythromycin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With domperidone, QT prolongation and torsade de pointes have been reported very rarely, and these reports included people with other risk factors, electrolyte disturbances or concomitant medicines (domperidone SmPC, AEMPS). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and names erythromycin among these antibiotics (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The erythromycin documents do not name domperidone. The Spanish erythromycin SmPC says to use erythromycin with caution in people taking other QT-prolonging drugs, to closely monitor the levels of drugs metabolised by cytochrome P450 enzymes and to adjust their dose if needed (erythromycin SmPC, AEMPS). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances, bradycardia and heart disease such as congestive heart failure (AEMPS). Do not give erythromycin to people with a history of QT prolongation or ventricular arrhythmia, including torsade de pointes, or with low potassium or magnesium (erythromycin SmPC, AEMPS). Use domperidone at the lowest effective dose, no more than 30 mg a day in adults, and usually for no longer than one week (domperidone SmPC, AEMPS). No document says how long to wait after stopping erythromycin before starting domperidone. The elimination half-life of erythromycin is about 2 hours (erythromycin SmPC, AEMPS). If domperidone and erythromycin have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: E.E.S. (erythromycin ethylsuccinate) prescribing information (2025)– FDA, DailyMed, Carnegie Pharmaceuticals LLC, setid 91479d92-3bf3-4eb3-81bd-8ce4956d4347, revised 02/2025, Contraindications, Warnings – QT Prolongation, Precautions – Drug Interactions
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Eritromicina (nº registro 55771), sección 4.5 (2025)– AEMPS, CIMA, nº registro 55771 (Pantomicina 1 g polvo para solución para perfusión, Amdipharm), revisión 09/2025 (texto revisado 02/2023), secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Eritromicina (nº registro 58767), sección 4.3 (2025)– AEMPS, CIMA, nº registro 58767 (Pantomicina 100 mg/ml granulado para suspensión oral, Amdipharm), revisión 11/2025 (texto revisado 05/2024), secciones 4.3, 4.4 y 4.5